ContraFect (CFRX) Announces Proposed Public Offering of Common Stock and Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
ContraFect (CFRX) Prices 11.797M Share & Warrants Offering at $4.90/Sh
May 22, 2020 6:02 AM EDTContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an... More
